These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

269 related items for PubMed ID: 2783243

  • 21. Interleukin-2 and lymphokine activated killer cells: promises and cautions.
    Glassman AB.
    Ann Clin Lab Sci; 1989; 19(1):51-5. PubMed ID: 2644890
    [Abstract] [Full Text] [Related]

  • 22. In vivo administration of purified human interleukin 2. I. Half-life and immunologic effects of the Jurkat cell line-derived interleukin 2.
    Lotze MT, Frana LW, Sharrow SO, Robb RJ, Rosenberg SA.
    J Immunol; 1985 Jan; 134(1):157-66. PubMed ID: 3871099
    [Abstract] [Full Text] [Related]

  • 23. Autologous peripheral blood stem cell transplantation and adoptive immunotherapy with activated natural killer cells in the immediate posttransplant period.
    Lister J, Rybka WB, Donnenberg AD, deMagalhaes-Silverman M, Pincus SM, Bloom EJ, Elder EM, Ball ED, Whiteside TL.
    Clin Cancer Res; 1995 Jun; 1(6):607-14. PubMed ID: 9816022
    [Abstract] [Full Text] [Related]

  • 24. Clinical and immunological effects of granulocyte-macrophage colony-stimulating factor coadministered with interleukin 2: a phase IB study.
    Schiller JH, Hank JA, Khorsand M, Storer B, Borchert A, Huseby-Moore K, Burns D, Wesly O, Albertini MR, Wilding G, Sondel PM.
    Clin Cancer Res; 1996 Feb; 2(2):319-30. PubMed ID: 9816175
    [Abstract] [Full Text] [Related]

  • 25. Transient decrease in IL-2-responsive lymphocytes 24 hours after initiation of continuous IL-2 infusion in cancer patients.
    Weil-Hillman G, Hank JA, Rosenthal NS, Sondel PM.
    J Biol Response Mod; 1988 Oct; 7(5):424-37. PubMed ID: 3053997
    [Abstract] [Full Text] [Related]

  • 26. [Immunotherapy of tumors using interleukin-2 and lymphokine-activated killer cells].
    Jost LM, Gmür J, Oelz O, Sauter C, Stahel RA.
    Schweiz Med Wochenschr; 1988 Feb 04; 119(5):137-43. PubMed ID: 3266369
    [Abstract] [Full Text] [Related]

  • 27. Identification and selection of human lymphokine activated killer cell effectors and novel recycling intermediates by unique light-scattering properties.
    Loudon WG, Abraham SR, Owen-Schaub LB, Hemingway LL, Hemstreet GP, DeBault LE.
    Cancer Res; 1988 Apr 15; 48(8):2184-92. PubMed ID: 3258186
    [Abstract] [Full Text] [Related]

  • 28. Interleukin 2 expanded tumor-infiltrating lymphocytes in human renal cell cancer: isolation, characterization, and antitumor activity.
    Belldegrun A, Muul LM, Rosenberg SA.
    Cancer Res; 1988 Jan 01; 48(1):206-14. PubMed ID: 3257161
    [Abstract] [Full Text] [Related]

  • 29. Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity.
    Miller JS, Tessmer-Tuck J, Pierson BA, Weisdorf D, McGlave P, Blazar BR, Katsanis E, Verfaillie C, Lebkowski J, Radford J, Burns LJ.
    Biol Blood Marrow Transplant; 1997 Apr 01; 3(1):34-44. PubMed ID: 9209739
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Toxicity and immunologic effects of continuous infusion of recombinant human interleukin-2 administered by selective hepatic perfusion in dogs.
    Da Pozzo LF, Hough KL, Holder WD.
    Surgery; 1992 Mar 01; 111(3):326-34. PubMed ID: 1542858
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Systemic interleukin-2 and adoptive transfer of lymphokine-activated killer cells improves antibody-dependent cellular cytotoxicity in patients with relapsed B-cell lymphoma treated with rituximab.
    Berdeja JG, Hess A, Lucas DM, O'Donnell P, Ambinder RF, Diehl LF, Carter-Brookins D, Newton S, Flinn IW.
    Clin Cancer Res; 2007 Apr 15; 13(8):2392-9. PubMed ID: 17438098
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I/II trial.
    Burns LJ, Weisdorf DJ, DeFor TE, Vesole DH, Repka TL, Blazar BR, Burger SR, Panoskaltsis-Mortari A, Keever-Taylor CA, Zhang MJ, Miller JS.
    Bone Marrow Transplant; 2003 Jul 15; 32(2):177-86. PubMed ID: 12838283
    [Abstract] [Full Text] [Related]

  • 38. High-dose continuous intravenous infusion of interleukin-2 therapy for metastatic renal cell carcinoma: the University of Chicago experience.
    Shulman KL, Stadler WM, Vogelzang NJ.
    Urology; 1996 Feb 15; 47(2):194-7. PubMed ID: 8607232
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. A new approach to generating antitumor effectors for adoptive immunotherapy using human adherent lymphokine-activated killer cells.
    Melder RJ, Whiteside TL, Vujanovic NL, Hiserodt JC, Herberman RB.
    Cancer Res; 1988 Jun 15; 48(12):3461-9. PubMed ID: 3259468
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.